SABS — SAB Biotherapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $259.71m
- $166.39m
Annual cashflow statement for SAB Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -17.1 | -18.7 | -42.2 | -34.1 | 13.3 |
| Depreciation | |||||
| Non-Cash Items | 5.79 | -7.77 | 11 | -2.68 | -57.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 11.7 | -0.238 | 2.33 | -2.3 | -3.69 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 1.99 | -23.5 | -25.1 | -34.3 | -44.8 |
| Capital Expenditures | -10.9 | -2.17 | -0.197 | -0.337 | -0.933 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | 0.076 | 0.044 | -11.6 | -121 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -10.9 | -2.09 | -0.153 | -12 | -122 |
| Financing Cash Flow Items | — | — | — | -0.286 | -0.012 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 35.9 | 1.05 | 66.8 | -1.17 | 168 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 26.9 | -24.5 | 41.5 | -47.7 | 1.6 |